Clinically occult tubal and ovarian high-grade serous carcinomas presenting in uterine samples: Diagnostic pitfalls and clues to improve recognition of tumor origin

International Journal of Gynecological Pathology

Volumn 32, Issue 5, 2013, Pages 433-443

  Bagby, Christina ^a   Ronnett, Brigitte M ^a,b   Yemelyanova, Anna ^a   Maleki, Zahra ^a   Kuhn, Elisabetta ^a   Vang, Russell ^a,b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Endocervical curettage; Endometrial biopsy; Fallopian tube; High grade serous carcinoma; Ovary

Indexed keywords

CA 125 ANTIGEN; TUMOR MARKER; WT1 PROTEIN; WT1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; ENDOMETRIUM BIOPSY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; MYOMECTOMY; OVARY CARCINOMA; PAPANICOLAOU TEST; PHYSICAL EXAMINATION; PLEURA EFFUSION; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY; TUMOR VOLUME; UTERUS; BIOPSY; CANCER GRADING; CLASSIFICATION; CURETTAGE; CYSTADENOCARCINOMA, SEROUS; EPITHELIUM CELL; FALLOPIAN TUBE NEOPLASMS; METABOLISM; MIDDLE AGED; OVARIAN NEOPLASMS; PATHOLOGY; UTERINE TUBE; VAGINA SMEAR;

AGED; BIOPSY; CURETTAGE; CYSTADENOCARCINOMA, SEROUS; DIAGNOSIS, DIFFERENTIAL; EPITHELIAL CELLS; FALLOPIAN TUBE NEOPLASMS; FALLOPIAN TUBES; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM GRADING; OVARIAN NEOPLASMS; PAPANICOLAOU TEST; PLEURAL EFFUSION; TUMOR MARKERS, BIOLOGICAL; VAGINAL SMEARS; WT1 PROTEINS;

EID: 84883463832     PISSN: 02771691     EISSN: 15387151     Source Type: Journal    
DOI: 10.1097/PGP.0b013e31826a6446     Document Type: Article

References (52)

1. Euscher ED, Silva EG, Deavers MT, et al. Serous carcinoma of the ovary, fallopian tube, or peritoneum presenting as lymphadenopathy. Am J Surg Pathol 2004;28:1217-23.
2. Recine MA, Deavers MT, Middleton LP, et al. Serous carcinoma of the ovary and peritoneum with metastases to the breast and axillary lymph nodes: a potential pitfall. Am J Surg Pathol 2004;28:1646-51.
3. Baekelandt M, Jorunn NA, Kristensen GB, et al. Carcinoma of the fallopian tube. Cancer 2000;89:2076-84.
4. Eddy GL, Copeland LJ, Gershenson DM, et al. Fallopian tube carcinoma. Obstet Gynecol 1984;64:546-52.
5. Gupta D, Balsara G. Extrauterine malignancies. Role of pap smears in diagnosis and management. Acta Cytol 1999;43:806-13.
6. Mulvany NJ, Mitchell G, Allen DG. Adenocarcinoma cells in Pap smears. Pathology 2009;41:411-8.
7. Schnatz PF, Guile M, O'Sullivan DM, et al. Clinical significance of atypical glandular cells on cervical cytology. Obstet Gynecol 2006;107:701-8.
8. Zhao C, Austin RM, Pan J, et al. Clinical significance of atypical glandular cells in conventional pap smears in a large, high-risk U.S. west coast minority population. Acta Cytol 2009;53:153-9.
9. Zhao C, Florea A, Onisko A, et al. Histologic follow-up results in 662 patients with Pap test findings of atypical glandular cells: results from a large academic women's hospital laboratory employing sensitive screening methods. Gynecol Oncol 2009;114:383-9.
10. Alvarado-Cabrero I, Young RH, Vamvakas EC, et al. Carcinoma of the fallopian tube: a clinicopathological study of 105 cases with observations on staging and prognostic factors. Gynecol Oncol 1999;72:367-79.
11. Hirai Y, Chen JT, Hamada T, et al. Clinical and cytologic aspects of primary fallopian tube carcinoma. A report of ten cases. Acta Cytol 1987;31:834-40.
12. Peters WA, III Andersen WA, Hopkins MP, et al. Prognostic features of carcinoma of the fallopian tube. Obstet Gynecol 1988;71:757-62.
13. Sasagawa M, Nishino K, Honma S, et al. Origin of adenocarcinoma cells observed on cervical cytology. Acta Cytol 2003;47:410-4.
14. Takashina T, Ito E, Kudo R. Cytologic diagnosis of primary tubal cancer. Acta Cytol 1985;29:367-72.
15. Abdul-Karim FW, Bennert KW, Macfee M. Accidental detection of nonmetastatic ovarian adenocarcinoma in tissue samples recovered during dilatation and curettage. Int J Gynecol Pathol 1993;12:355-9.
16. Maki C, Groen J, Delgado B, et al. Cervical metastasis as the first manifestation of ovarian papillary serous carcinoma. J Obstet Gynaecol 2010;30:325-6.
17. Malpica A, Deavers MT. Ovarian low-grade serous carcinoma involving the cervix mimicking a cervical primary. Int J Gynecol Pathol 2011;30:613-9.
18. McComas BC, Farnum JB, Donaldson RC. Ovarian carcinoma presenting as a cervical metastasis. Obstet Gynecol 1984;63:593-6.
19. Himmetoglu C, Usubutun A, Ayhan A, et al. Incidental serous papillary ovarian carcinoma diagnosed on endometrial biopsy. Turk J Pathol 2008;24:186-9.
20. Przybycin CG, Kurman RJ, Ronnett BM, et al. Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol 2010;34:1407-16.
21. Vang R, Wheeler JE. Diseases of the fallopian tube and paratubal region. In: Kurman RJ, Ellenson LH, Ronnett B, eds. Blaustein's Pathology of the Female Genital Tract.; 6th ed New York: Springer; 2011:529-78.
22. Bloss JD, Liao SY, Buller RE, et al. Extraovarian peritoneal serous papillary carcinoma: a case-control retrospective comparison to papillary adenocarcinoma of the ovary. Gynecol Oncol 1993;50:347-51.
23. Kuhn E, Kurman RJ, Vang R, et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic highgrade serous carcinoma-evidence supporting the clonal relationship of the two lesions. J Pathol 2012;226:421-6.
24. McCluggage WG, Soslow RA, Gilks CB. Patterns of p53 immunoreactivity in endometrial carcinomas: 'all or nothing' staining is of importance. Histopathology 2011;59:786-8.
25. Yemelyanova A, Ji H, IeM Shih, et al. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases. Am J Surg Pathol 2009;33:1504-14.
26. Yemelyanova A, Vang R, Kshirsagar M, et al. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol 2011;24:1248-53.
27. Agoff SN, Mendelin JE, Grieco VS, et al. Unexpected gynecologic neoplasms in patients with proven or suspected BRCA-1 or -2 mutations: implications for gross examination, cytology, and clinical follow-up. Am J Surg Pathol 2002; 26:171-8.
28. Carcangiu ML, Peissel B, Pasini B, et al. Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature. Am J Surg Pathol 2006;30:1222-30.
29. Finch A, Shaw P, Rosen B, et al. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol 2006;100:58-64.
30. Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006;30:230-6.
31. Olivier RI, van Beurden M, Lubsen MA, et al. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. Br J Cancer 2004;90:1492-7.
32. Rabban JT, Krasik E, Chen LM, et al. Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingo-oophorectomies from women with BRCA mutations: implications for defining an optimal specimen dissection protocol. Am J Surg Pathol 2009;33:1878-85.
33. Yates MS, Meyer LA, Deavers MT, et al. Microscopic and early-stage ovarian cancers in BRCA1/2 mutation carriers: Building a model for early BRCA-associated tumorigenesis. Cancer Prev Res (Phila) 2011;4:463-70.
34. Espinosa I, Catasus L, Canet B, et al. Gene expression analysis identifies two groups of ovarian high-grade serous carcinomas with different prognosis. Mod Pathol 2011;24:846-54.
35. Malpica A, Deavers MT, Lu K, et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 2004;28:496-504.
36. Laki F, Kirova YM, This P, et al. Prophylactic salpingooophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation. Cancer 2007;109:1784-90.
37. Powell CB, Chen LM, McLennan J, et al. Risk-reducing salpingo- oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol. Int J Gynecol Cancer 2011;21:846-51.
38. Vang R, IeM Shih, Kurman RJ. Ovarian low-grade and highgrade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 2009;16:267-82.
39. Hashi A, Yuminamochi T, Murata S, et al. Wilms tumor gene immunoreactivity in primary serous carcinomas of the fallopian tube, ovary, endometrium, and peritoneum. Int J Gynecol Pathol 2003;22:374-7.
40. Kobel M, Kalloger SE, Carrick J, et al. A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol 2009;33:14-21.
41. Coosemans A, Moerman P, Verbist G, et al. Wilms' tumor gene 1 (WT1) in endometrial carcinoma. Gynecol Oncol 2008;111:502-8.
42. Goldstein NS, Uzieblo A. WT1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas. Am J Clin Pathol 2002;117:541-5.
43. Al-Hussaini M, Stockman A, Foster H, et al. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology 2004;44:109-15.
44. Egan JA, Ionescu MC, Eapen E, et al. Differential expression of WT1 and p53 in serous and endometrioid carcinomas of the endometrium. Int J Gynecol Pathol 2004;23:119-22.
45. Acs G, Pasha T, Zhang PJ. WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium. Int J Gynecol Pathol 2004;23:110-8.
46. McCluggage WG, McBride HA. Papillary syncytial metaplasia associated with endometrial breakdown exhibits an immunophenotype that overlaps with uterine serous carcinoma. Int J Gynecol Pathol 2012;31:206-10.
47. Nicolae A, Preda O, Nogales FF. Endometrial metaplasias and reactive changes: a spectrum of altered differentiation. J Clin Pathol 2011;64:97-106.
48. Quddus MR, Sung CJ, Zheng W, et al. P53 immunoreactivity in endometrial metaplasia with dysfunctional uterine bleeding. Histopathology 1999;35:44-9.
49. Tarraza HM, Muntz HG, De Cain M, et al. Cervical metastases in advanced ovarian malignancies. Eur J Gynaecol Oncol 1993;14:274-8.
50. Snyder MJ, Bentley R, Robboy SJ. Transtubal spread of serous adenocarcinoma of the endometrium: an underrecognized mechanism of metastasis. Int J Gynecol Pathol 2006;25:155-60.
51. Jarboe EA, Miron A, Carlson JW, et al. Coexisting intraepithelial serous carcinomas of the endometrium and fallopian tube: frequency and potential significance. Int J Gynecol Pathol 2009;28:308-15.
52. Stewart CJ, Armstrong M, Brennan BA, et al. Coexisting serous carcinoma of the endometrium and the fallopian tube. Int J Gynecol Pathol 2010;29:278-81.